Advancing innovation and translation: Czernin interviews Kalevi Kairemo, president-elect of the World Association of Radiopharmaceutical and Molecular Therapy, about a diverse career in pioneering novel radiolabeled therapeutics.
Page 1671
FAPI in rheumatologic disorders: Schmidkonz and colleagues offer perspective on the current and future potential of fibroblast-activation protein inhibitor PET in noninvasive characterization of rheumatoid arthritis, lung fibrosis, and IgG4-related disease.
Page 1674
Development of infection tracers: Signore and participants summarize the consensus results of a 2022 International Atomic Energy Agency technical meeting focused on the use of radiolabeled agents for imaging of bacterial infection.
Page 1676
IDH mutation and metabolic heterogeneity: Lohmeier and colleagues investigate metabolic reprogramming of glioma using compartmental uptake characteristics in 18F-FET PET and evaluate the diagnostic potential for isocitrate dehydrogenase genotyping.
Page 1683
Imaging biomarkers in breast cancer: Hennessy and colleagues ask whether 18F-FDG PET/CT lean body mass parameters can predict recurrence-free and overall survival in patients with estrogen receptor–negative, HER2-positive breast cancer and neoadjuvant trastuzumab and pertuzumab therapy.
Page 1690
18F-FDG PET breast cancer therapy response: Gebhart provides context and commentary on the potential of 18F-FDG PET assessment of metabolic response in neoadjuvant systemic therapy for breast cancer.
Page 1697
18F-FDOPA PET and prognosis in midgut NETs: De Rycke and colleagues explore the prognostic role of 18F-FDOPA PET/CT tumor uptake in metastatic midgut neuroendocrine tumors.
Page 1699
ΔSUVmax for interim PET in DLBCL: Itti and colleagues use phase 3 trial data from patients with diffuse large B-cell lymphoma to compare the prognostic value of PET protocol interpretation criteria with that of change in SUVmax alone.
Page 1706
68Ga-FAPI PET/CT impact on management: Koerber and colleagues analyze the clinical impact of 68Ga-fibroblast-activation protein inhibitor PET/CT in staging and management in a large cohort of patients with various tumors.
Page 1712
ctDNA biomarkers and 177Lu-PSMA: Sartor and colleagues investigate pretreatment circulating tumor DNA findings, including gene amplifications, in responders and nonresponders to 177Lu-PSMA–based therapies for metastatic castration-resistant prostate cancer.
Page 1721
177Lu-PSMA-617 vs docetaxel in mCRPC: Satapathy and colleagues report on final analysis of overall survival for a phase 2 randomized trial of 177Lu-PSMA-617 and docetaxel in chemotherapy-naïve metastatic castration-resistant prostate cancer patients.
Page 1726
Antihormonal treatment and 68Ga-PSMA-11: Kluge and colleagues explore the effects of androgen deprivation therapy on PSMA ligand biodistribution and discuss implications for treatment-optimizing and side-effect–minimizing strategies for PSMA radioligand therapies.
Page 1730
End-of-treatment PSMA PET: Murthy and colleagues assess the prognostic value of end-of-treatment PSMA PET/CT in patients with metastatic castration-resistant prostate cancer treated with 177Lu-PSMA radioligand therapy.
Page 1737
Bone scan vs PSMA PET: Hope and colleagues evaluate the ability of bone scans to detect osseous metastases from prostate cancer at initial staging using PSMA PET as a reference standard.
Page 1744
Redefining prostate cancer imaging: Eifer and colleagues provide commentary on the current dynamic landscape of prostate cancer imaging and on the challenges and promise of integrating PSMA PET/CT findings into clinical treatment decision-making.
Page 1748
PSMA PET to predict csPCa: Zhang and colleagues introduce a PSMA PET–based model to improve the diagnostic accuracy of clinically significant prostate cancer in patients with preoperative Gleason grade group 1 biopsy.
Page 1750
Response prediction for PSMA therapy: Hohberg and colleagues analyze 177Lu-PSMA absorbed doses in osseous versus lymphatic metastases in patients with metastatic castration-resistant prostate cancer across therapy cycles and relate those data, along with pretherapeutic PSMA PET, to therapeutic success.
Page 1758
HRQoL with mCRPC after PSMA RLT: Karimzadeh and colleagues use the European Organisation for Research and Treatment of Cancer quality-of-life questionnaire to assess health-related metrics for patients with metastatic castration-resistant prostate cancer receiving consecutive cycles of 177Lu therapy.
Page 1765
Tandem 177Lu/225Ac PSMA RLT in mice: Meyer and colleagues directly compare α- and β-particle PSMA treatment, as well as a combination of the 2, at different stages of disease in a murine model of disseminated prostate cancer.
Page 1772
Combined [177Lu]Lu-PSMA-617 RPT and SBRT: Grkovski and colleagues describe a pilot trial of the feasibility of combining [177Lu]Lu-PSMA-617 treatment with stereotactic body radiotherapy in patients with oligometastatic castration-sensitive prostate cancer.
Page 1779
MRT radiobiology symposium: Nonnekens and participants summarize research and insights from the second International Workshop on Radiobiology of Molecular Radiotherapy, held in London in 2023.
Page 1788
203Pb production with electroplated 205Tl: Saini and colleagues detail optimization of production and separation of high-specific-activity 203Pb using electroplated thallium targets and propose associated radiochemistry enhancements.
Page 1791
Tau threshold biostatistical estimation: Gogola and colleagues compare multiple tau PET threshold-determining methods in study participants undergoing 18F-flortaucipir or 18F-MK-6240 imaging.
Page 1798
PET imaging of IL12/23p40 in IBD: Rezazadeh and colleagues describe the potential of immuno-PET to image inflammation in a chemically induced mouse model of colitis by targeting IL12/23p40 with an 89Zr-radiolabeled anti-IL12/23p40 antibody.
Page 1806
LAFOV 89Zr immuno-PET: Mohr and colleagues look at SUV differences between 89Zr immuno-PET scans obtained using PET/CT systems with long and standard axial fields of view and at how LAFOV PET scan duration affects image noise and SUV metrics.
Page 1815
Total-body dynamic PET and COVID recovery: Wang and colleagues demonstrate quantification of glucose metabolism using total-body multiparametric 18F-FDG PET and assess specific glucose delivery and phosphorylation processes for studying COVID recovery.
Page 1821
[11C]-Butanol total-body perfusion: Li and colleagues report on a pilot study using [11C]-butanol imaging on the uEXPLORER total-body PET/CT scanner for quantitative measurement of perfusion across the entire body.
Page 1831
Sialadenitis on PET: Maliha and colleagues present findings from [68Ga]Ga-FAPI-46 PET and [18F]FDG PET in a case of obstructive sialadenitis from oral squamous cell carcinoma.
Page 1839
- © 2023 by the Society of Nuclear Medicine and Molecular Imaging.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.